ARDX
ArdelyxCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
Current thesis
The long thesis is primarily a commercial-execution story: IBSRELA grew 73% to $274.2M in 2025, management guides another step-up to $410-430M in 2026, and the company added a formulation patent running to November 26, 2042 for IBSRELA/XPHOZAH commercial formulations [#8-K-2026-02-19] [#10-K-2026-02-19].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +17.1.
What can break
2026 operating-expense growth could absorb commercial upside and delay durable cash-flow inflection.
Momentum
34
Value
41
Sentiment
89
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.00 · Bull $11.50 · Bear $4.20
Data freshness
Prices
As of 2026-06-03
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-03 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-03
Investment thesis
As of 2026-06-03
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $16.10
Why
Momentum34 · Δ7d -15.6
Value41 · Δ7d +0.0
Sentiment89 · Δ7d +17.1
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
34
34% active weight
Current posture
7d trendSoftening
Δ7d
-15.6
Δ21d
-25.2
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.2
Sentiment
89
33% active weight
Current posture
7d trendImproving
Δ7d
+17.1
Δ21d
+30.9
Why this grade
Composite grade C. Momentum 34.2 / Value 41.1 / Sentiment 89.5
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$1.36B
Beta
0.56
Shares Out
242.97M
P/E (TTM) · Derived
-22.0
P/S (TTM)
3.72
P/FCF (TTM) · Derived
-24.28
Rev YoY
+12.3%
EPS YoY
-16.9%
Gross Margin
+88.2%
Op Margin
-9.5%
Net Debt
-$99.25M
Current Ratio
4.41
As of 2026-06-03 • Updated nightlySource: Internal modelMethodology